Proteomics, morphoproteomics, saliva and breast cancer: An emerging approach to guide the delivery of individualised thermal therapy, thermochemotherapy and monitor therapy response

International Journal of Hyperthermia

Volumn 26, Issue 7, 2010, Pages 649-661

  Streckfus, Charles F ^a   Brown, Robert E ^b   Bull, Joan M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Morphoproteomics; Proteomics; Saliva; Signal transduction pathways

Indexed keywords

CA 125 ANTIGEN; PROHIBITIN; RAF PROTEIN;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER TISSUE; DIAGNOSTIC TEST; ENZYME ACTIVATION; HEAD AND NECK CANCER; HUMAN; LASER CAPTURE MICRODISSECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MORPHOPROTEOMICS; OVARY CANCER; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SALIVA; SALIVARY PROTEOMICS; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TISSUE SECTION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; PROTEOMICS; SALIVA;

EID: 77956903151     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2010.506470     Document Type: Review

References (71)

1. Pasa-Tolic L, Masselon C, Barry RC, Shen Y, Smith RD. Proteomic analyses using an accurate mass and time tag strategy. Biotechniques 2004;37:621-639.
2. Silva JC, Denny R, Dorschel CA, Gorenstein M, Kass IJ, Li GZ, McKenna T, Nold MJ, Richardson K, Young P, et al. Quantitative proteomic analysis by accurate mass retention time pairs. Anal Chem 2005;77:2187-2200.
3. Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ. Absolute quantification of proteins by LCMSE: A virtue of parallel MS acquisition. Mol Cell Proteomics 2006;5:144-156.
4. Pan C, Olsen JV, Daub H, Mann M. Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 2009;8:2796-2808.
5. Villen J, Beausoleil SA, Gerber SA, Gygi SP. Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci USA 2007;104:1488-1493.
6. Amann JM, Chaurand P, Gonzalez A, Mobley JA, Massion PP, Carbone DP, Caprioli RM. Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spec-trometry. Clin Cancer Res 2006;12:5142-5150.
7. Patel V, Hood BL, Molinolo AA, Lee NH, Conrads TP, Braisted JC, Krizman DB, Veenstra TD, Gutkind JS. Proteomic analysis of laser-captured paraffin-embedded tissues: A molecular portrait of head and neck cancer progression. Clin Cancer Res 2008;14:1002-1014.
8. Rodriguez AS, Espina BH, Espina V, Liotta LA. Automated laser capture microdissection for tissue proteomics. Methods Mol Biol 2008;441:71-90.
9. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: A tutorial. Mol Syst Biol 2008;4:1-14.
10. Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics 2010;9:184-196.
11. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
12. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22.
13. Hodgkinson VC, Eagle GL, Drew PJ, Lind MJ, Cawkwell L. Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: Current status. Cancer Lett 2010; 294:13-24.
14. Brown RE. Morphoproteomics: Exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics 2005;2:337-348.
15. Havaleshko DM, Smith SC, Cho H, Cheon S, Owens CR, Lee JK, Liotta LA, Espina V, Wulfkuhle JD, Petricoin EF, et al. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia 2009;11:1185-1193.
16. Petricoin EF. Proteomics in laboratory medicine. Preface. Clin Lab Med 2009;29:xiii-xiv.
17. Streckfus CF, Storthz KA, Bigler L, Dubinsky WP. A comparison of the proteomic expression in pooled saliva specimens from individuals diagnosed with ductal carcinoma of the breast with and without lymph node involvement. J Oncol 2010;2009:1-11.
18. Brown RE, Tan D, Taylor JS, Miller M, Prichard JW, Kott MM. Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in high risk neuro-blastoma, with cell cycle and protein analyte correlates. Ann Clin Lab Sci 2007;37:141-147.
19. Brown RE, Boyle JL. Mesenchymal chondrosarcoma: Molecular characterization by a proteomic approach, with morphogenic and therapeutic implications. Ann Clin Lab Sci 2003;33:131-141.
20. Tan D. Morphoproteomics: A novel approach to identify potential therapeutic targets in cancer patients. Int J Clin Exp Pathol 2008;1:331-332.
21. Brown RE, Bostrom B, Zhang PL. Morphoproteomics and bortezomib/ dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann Clin Lab Sci 2004; 34:203-205.
22. He J, Shen D, Chung DU, Saxton RE, Whitelegge JP, Faull KF, Chang HR, et al. Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy. Int J Oncol. 2009;35:683-692.
23. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, et al. The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009;8:3984-4001.
24. Smith L, Qutob O, Watson MB, Beavis AW, Potts D, Welham KJ, Garimella V, Lind MJ, Drew PJ, et al. Proteomic identification of putative biomarkers of radiotherapy resistance: A possible role for the 26S proteasome? Neoplasia 2009;11:1194-1207.
25. Brown RE. Morphogenomics and morphoproteomics: A role for anatomic pathology in personalized medicine. Arch Pathol Lab Med 2009;133:568-579.
26. Streckfus CF, Mayorga-Wark O, Arreola D, Edwards C, Bigler L, Dubinsky WP. Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast. Cancer Invest. 2008 Mar;26(2):159-167
27. Feng W, Brown RE, Trung CD, Li W, Wang L, Khoury T, Alrawi S, Yao J, Xia K, Tan D. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci 2008;38:195-209.
28. Brown RE, Lun M, Prichard JW, Blasick TM, Zhang PL. Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines. Ann Clin Lab Sci 2004;34:251-262.
29. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467.
30. National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001;30:5-15.
31. Buzdar AU. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol 2009;20:993-999.
32. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data ofadditional patients treated with the same regimen. Clin Cancer Res 2007;13:228-233.
33. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007;120:1874-1882.
34. Robertson JF, Steger GG, Neven P, Barni S, Gieseking F, Nole F, Pritchard KI, O'Malley FP, Simon SD, Kaufman B, et al. Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Ann Oncol 2010;21:1246-1253.
35. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009;101:1308-1324.
36. Brown RE, Law A. Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma multiforme with genomic correlates and therapeutic implications. Ann Clin Lab Sci 2006;36:421-426.
37. Brown RE. Morphoproteomic portrait of the mTOR pathway in mesenchymal chondrosarcoma. Ann Clin Lab Sci 2004; 34:397-399.
38. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003;362:433-439.
39. Crecelius AC, Cornett DS, Caprioli RM, Williams B, Dawant BM, Bodenheimer B. Three-dimensional visualization of protein expression in mouse brain structures using imaging mass spectrometry. J Am Soc Mass Spectrom 2005; 16:1093-1099.
40. Simonetti AW, Melssen WJ, vander Graaf M, Postma GJ, Heerschap A, Buydens LM. A chemometric approach for brain tumor classification using magnetic resonance imaging and spectroscopy. Anal Chem 2003;75:5352-5361.
41. Chaurand P, Sanders ME, Jensen RA, Caprioli RM. Proteomics in diagnostic pathology: Profiling and imaging proteins directly in tissue sections. Am J Pathol 2004; 165:1057-1068.
42. Chaurand P, Schwartz SA, Caprioli RM. Assessing protein patterns in disease using imaging mass spectrometry. J Proteome Res 2004;3:245-252.
43. Noben JP, Dumont D, Kwasnikowska N, Verhaert P, Somers V, Hupperts R, Stinissen P, Robben J. Lumbar cerebrospinal fluid proteome in multiple sclerosis: Characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J Proteome Res 2006;5:1647-1657.
44. Bigler LR, Streckfus CF, Dubinsky WP. Salivary biomarkers for the detection ofmalignant tumors that are remote from the oral cavity. Clin Lab Med 2009;29:71-85.
45. Hu S, Xie Y, Ramachandran P, Ogorzalek Loo RR, Li Y, Loo JA, Wong DT. Large-scale identification ofproteins in human salivary proteome by liquid chromatography/mass spectro-metry and two-dimensional gel electrophoresis-mass spectro-metry. Proteomics. 2005;5:1714-1728.
46. Streckfus CF, Bigler LR. Saliva as a diagnostic fluid. Oral Dis 2002;8:69-76.
47. Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin III EF, Liotta L. approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol 2003;532:59-68.
48. Bandhakavi S, Stone MD, Onsongo G, Van Riper SK, Griffin TJ. A dynamic range compression and three-dimensional peptide fractionation analysis platform expands proteome coverage and the diagnostic potential of whole saliva. J Proteome Res 2009;8:5590-5600.
49. Luther T, Carrion CF, Cobb N, Le G, Edwards C, Schwartz S, Streckfus C. Methods for analyzing saliva proteins for systemic disease detection. Gen Dentis 2010;58:110-113.
50. Denny P, Hagen FK, Hardt M, Liao L, Yan W, Arellanno M, Bassilian S, Bedi GS, Boontheung P, Cociorva D, et al. The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. J Proteome Res 2008;7:1994-2006.
51. Michener CM, Ardekani AM, Petricoin III EF, Liotta LA, Kohn EC. Genomics and proteomics: Application of novel technology to early detection and prevention of cancer. Cancer Detect Prev 2002;26:249-255.
52. Yates III JR, McCormack AL, Schieltz D, Carmack E, Link A. Direct analysis of protein mixtures by tandem mass spectro-metry. J Protein Chem 1997;16:495-497.
53. Rasmussen HH, Mortz E, Mann M, Roepstorff P, Celis JE. Identification of transformation sensitive proteins recorded in human two-dimensional gel protein databases by mass spectrometric peptide mapping alone and in combination with microsequencing. Electrophoresis 1994;15:406-416.
54. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomarker Insights 2006;2:1-48.
55. Wang-Su ST, McCormack AL, Yang S, Hosler MR, Mixon A, Riviere MA, Wilmarth PA, Andley UP, Garland D, Li H, et al. Proteome analysis oflens epithelia, fibers, and the HLE B-3 cell line. Invest Ophthalmol Vis Sci 2003;44:4829-4836.
56. Gu S, Liu Z, Pan S, Jiang Z, Lu H, Amit O, Bradbury EM, Hu CA, Chen X. Global investigation of p53-induced apoptosis through quantitative proteomic profiling using comparative amino acid-coded tagging. Mol Cell Proteomics 2004;3:998-1008.
57. Wilmarth PA, Riviere MA, Rustvold DL, Lauten JD, Madden TE, David LL. Two-dimensional liquid chromatography study of the human whole saliva proteome. J Proteome Res 2004;3:1017-1023.
58. Shevchenko A, Chernushevic I, Wilm M, Mann M. 'De novo' sequencing of peptides recovered from in-gel digested proteins by nanoelectrospray tandem mass spectrometry. Mol Biotechnol 2002;20:107-118.
59. Koomen JM, Zhao H, Li D, Abbruzzese J, Baggerly K, Kobayashi R. Diagnostic protein discovery using proteolytic peptide targeting and identification. Rapid Commun Mass Spectrom 2004;18:2537-2548.
60. Ward LD, Reid GE, Moritz RL, Simpson RJ. Strategies for internal amino acid sequence analysis of proteins separated by polyacrylamide gel electrophoresis. J Chromatogr 1990; 519:199-216.
61. Beck M, Malmstrom JA, Lange V, Schmidt A, Deutsch EW, Aebersold R. Visual proteomics of the human pathogen Leptospira interrogans. Nat Methods 2009;6: 817-823.
62. Malmstrom J, Beck M, Schmidt A, Lange V, Deutsch EW, Aebersold R. Proteome-wide cellular protein concentrations of the human pathogen Leptospira interrogans. Nature 2009;460:762-765.
63. Wu SL, Kim J, Bandle RW, Liotta L, Petricoin E, Karger BL. Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using extended range proteomic analysis (ERPA). Mol Cell Proteomics 2006;5:1610-1627.
64. Wu SL, Hancock WS, Goodrich GG, Kunitake ST. An approach to the proteomic analysis of a breast cancer cell line (SKBR-3). Proteomics 2003;3:1037-1046.
65. Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, Babiera G, Hortobagyi GN, Valero V. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 2006;17:605-613.
66. Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Lakhani SR, Schmitt FC. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006; 49:10-21.
67. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009;69:4116-4124.
68. Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM. Identification of markers of taxane sensitivity using proteomic and geno-mic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res;16:681-690.
69. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lun Y, Zhang F, Coombes KR. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res;16:2852-2860.
70. Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C, Rapp UR, Rudel T. Prohibitin is required for RAS-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol 2005;7:837-843.
71. Eldridge AG, Loktev AV, Hansen DV, Verschuren EW, Reimann JD, Jackson PK. The evi5 oncogene regulates cyclin accumulation by stabilizing the anaphase-promoting complex inhibitor emi1. Cell 2006;124:367-380.